Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Are peptides legal in Indiana?

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

The short answer

Yes. An Indiana resident can obtain FDA approved peptides such as semaglutide and tirzepatide by prescription from an Indiana-licensed prescriber, including by telehealth under Indiana Code 25-1-9.5, which lets a prescriber issue a prescription to a telehealth patient the prescriber has not examined in person if the standard of care is met. Under that chapter, an Internet questionnaire with a new patient does not count as telehealth. Compounded peptides are available when eligible under federal 503A rules and dispensed by an Indiana pharmacy or a nonresident pharmacy licensed by the Indiana Board of Pharmacy. Indiana tightened compounding in 2026: Senate Enrolled Act 282, signed March 5, 2026, requires bulk drug substances used in compounding to come from FDA-registered manufacturers with a certificate of analysis and requires medical spas to register with the Medical Licensing Board beginning January 1, 2027.

Regulatory: Telehealth allowedRegulatory: Async unclearRegulatory: Compounded GLP-1 limitedVerified: Verified Oct 28, 2026
Compounding rules
Follows the federal 503A framework
Telehealth prescribing
Allowed, asynchronous unclear; a questionnaire alone is not enough
Compounded GLP-1
Limited

Can a Indiana resident get peptides by telehealth?

Indiana Code 25-1-9.5 (Telehealth Services and Prescriptions) holds a practitioner who uses telehealth to the in-person standard and requires a proper provider-patient relationship, which at a minimum means obtaining the patient's name, contact information, and location, verifying identity as far as reasonably possible, disclosing the practitioner's name and license, getting informed consent, obtaining the medical history needed for a diagnosis, discussing the diagnosis, the evidence for it, and the risks and benefits of treatment options with the patient, keeping a medical record, giving follow-up instructions, and providing a visit summary that lists any prescription (section 7). Section 8 lets a prescriber issue a prescription to a telehealth patient the prescriber has never examined in person if the standard of care is met and the drug is not an opioid (other than an approved opioid dependence drug) or an abortion inducing drug. It names a real-time, two-way audiovisual system only in the conditions for controlled substances, although section 8(a)(3)(A) says a prescription must meet the requirements of subsection (b), which is where that condition sits. Telehealth providers must hold an Indiana license (IC 25-1-9.5-3.5). Section 6 defines telehealth to include store and forward technology, but says that, unless the practitioner already has an established relationship with the patient, telehealth does not include electronic mail, an instant messaging conversation, facsimile, an Internet questionnaire, or an Internet consultation. This record leaves asynchronous prescribing unknown because the law is ambiguous: store and forward counts as telehealth and no real-time visit is named for non-controlled drugs, yet the online channels an asynchronous visit with a new patient would normally use are excluded and the practitioner must discuss the diagnosis with the patient. An Internet questionnaire with a new patient does not count as telehealth. [2]

How does the Indiana pharmacy board treat compounding?

Compounding regulator for Indiana
BoardIndiana Board of Pharmacy (Indiana Professional Licensing Agency)
Eligible substancesFollows the federal 503A framework

The Indiana Board of Pharmacy, administered by the Professional Licensing Agency, regulates pharmacies under Indiana Code Title 25, Article 26 and Title 856 of the Indiana Administrative Code. Indiana follows the federal 503A framework for which substances may be compounded (approved drug component, USP or NF monograph, or FDA 503A bulks list), and Senate Enrolled Act 282 (2026) adds a state layer: bulk drug substances used for compounding must be manufactured by an FDA-registered establishment and be accompanied by a certificate of analysis, with most provisions effective July 1, 2026. The same act creates medical spa registration with the Medical Licensing Board of Indiana starting January 1, 2027, including a responsible practitioner and serious adverse event reporting, which reaches weight-loss and wellness clinics that administer compounded drugs. Pharmacies outside Indiana that ship prescription drugs to Indiana patients must hold an Indiana nonresident pharmacy license under Indiana Code 25-26-17. The enrolled act (Public Law 136, signed March 5, 2026) adds Indiana Code 16-42-22.5, effective July 1, 2026, which bars compounding unless the bulk drug substance is not research grade (outside an IRB-approved study) or veterinary grade, was made by an establishment registered with FDA as a human drug establishment, comes with a valid certificate of analysis stating its identity, content, and country of original manufacture, and has had quality control testing, and unless the compounding complies with the federal Food, Drug, and Cosmetic Act and applicable USP chapters. On Board request, a nonresident pharmacy shipping compounded drugs into Indiana must document compliance, and sellers must keep bulk substance records for two years after the last lot expires. Sterile preparation standards are in the Board's rules at 856 IAC 1, Rule 30 (sterile pharmaceuticals). [1] [3] [4] [6] [7] [8]

Can you get compounded GLP-1s in Indiana?

Regulatory: Compounded GLP-1 limited

Compounded semaglutide and tirzepatide are limited to documented patient-specific needs after the FDA shortage allowances ended in 2025, and Indiana's 2026 law adds sourcing rules (FDA-registered bulk manufacturers with certificates of analysis) that exclude the unregistered active ingredient suppliers behind many cheap compounded GLP-1 products. Medical spas offering GLP-1 injections will need to register with the Medical Licensing Board from January 1, 2027. [6] [11]

Prices by channel: semaglutide cost, tirzepatide cost.

Approvals, shortage history, and prices for every GLP-1 we track are on the GLP-1 hub.

What is the legal access path in Indiana?

Access options

We may earn a commission from these links.

Prices are the partner's own and are not verified by PeptideAgent. You answer health questions after checkout, and the partner's clinician decides whether to prescribe.

Unsponsored access paths are checked against public regulatory records. Sponsored offers are the partner's and are labeled. Products labeled research use only are never listed.

Find a provider in Indiana

What you'll actually find in Indiana, and how to check

Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. [15] [16] [17]

No FDA oversight of the specific product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [18]

What Indiana has done

PeptideAgent has not found a board or legislative action on peptides in Indiana.

Other states have acted:

  • On August 19, 2026, Mississippi's medical, nursing, and pharmacy boards said no licensed provider may prescribe, recommend, supply, or administer a peptide that is not FDA approved, and that a consent form does not remove the provider's liability. [20] Mississippi law
  • Louisiana acted by statute: Act 374, in effect August 1, 2026, bars its licensing boards from prohibiting peptides only when they come from a pharmacy or outsourcing facility that complies with federal compounding law. It does not make any peptide eligible to compound. [21] [22] Louisiana law

Checking the prescriber

Telehealth prescribing of non-controlled peptides is permitted in Indiana. The state law we checked does not settle whether a prescription can be issued without a live visit, so expect one. State law says an online questionnaire alone is not enough. [2] The telehealth rule in full.

Checking the pharmacy

Look the pharmacy up yourself before you pay, including an out-of-state mail-order pharmacy. The pharmacy regulator is the Indiana Board of Pharmacy (Indiana Professional Licensing Agency); its license search: FDA BeSafeRx: state board of pharmacy license lookups. [19]

If you're going ahead anyway

These steps lower some risks. They do not make a compounded product safe, and FDA has not reviewed it. [18]

They do not change a peptide's legal status either. That depends on the peptide: for a withdrawn nomination such as BPC-157 or TB-500, a 503A pharmacy has no federal basis to compound it from bulk, with or without a prescription, while a few Category 1 substances, such as NAD+ and glutathione, are compounded under FDA's interim policy, with conditions. Each peptide page gives its status. [9] [23] [24]

Check the pharmacy's license. Look the pharmacy up yourself on your state board of pharmacy's license search; FDA's BeSafeRx page links every state's. If the pharmacy is not listed, or is not licensed in your state, do not use it. [19] [25] [26]

What a legitimate prescription and consult look like. Federal law lets a pharmacy compound only for an identified patient on a valid prescription. A legitimate prescriber is licensed in the state where you are, evaluates you, and tells you the drug is compounded and not FDA approved, and a telehealth company should say which pharmacy compounds it. A seller that needs no prescription, or a pharmacy with no pharmacist to answer questions, is a warning sign. [17] [26] [27]

Why this is safer than a research-use-only product. A state-licensed pharmacy answers to its state board and has a pharmacist you can reach. A product labeled "research use only" or "not for human consumption" has neither, and FDA treats such products sold for people as unapproved drugs. In a 2024 study of semaglutide sold online without a prescription, half of six orders never arrived, and every vial that did was rated probably substandard or falsified, held more drug than its label said, and contained endotoxin. Black-market growth peptides have also contained modified molecules the label did not name. Safer is not safe: compounded drugs can also be contaminated or have too much or too little active ingredient. [18] [28] [29] [30] [31] [32]

Check for:

  • A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [18]
  • A real evaluation by a licensed prescriber, not just an online form.
  • A certificate of analysis for the specific batch.

Questions to ask

  • Pharmacy: What is your license number, and are you licensed in my state? Then check it yourself on the state board's site. [19]
  • Telehealth company: Which pharmacy compounds and ships this, and is it a 503A pharmacy or a 503B outsourcing facility? [17]
  • Pharmacy: Is this made for me on a prescription written in my name? [27]
  • Prescriber: Are you licensed where I am, and will you evaluate me yourself rather than rely on a questionnaire? [17] [26]
  • Anyone offering it: Does anyone call it "FDA approved", "generic", or from an "FDA-approved pharmacy"? None of these is true of a compounded drug, so the claim is a red flag. [17]

What is offered for a specific peptide, and what FDA found, is on each peptide page.

Is it legal to buy research peptides in Indiana?

Only Indiana-licensed pharmacies, including licensed nonresident pharmacies, may dispense prescription drugs to Indiana patients, and Senate Enrolled Act 282 (2026) requires compounders to source bulk substances from FDA-registered establishments. Indiana Code 16-42-22.5, added by that act, expressly bars compounding with a research grade bulk substance outside an IRB-approved study. "Research use only" peptides sold for human injection are unapproved new drugs under federal law, are not dispensed by a pharmacist, and do not meet Indiana's new sourcing standard. [3] [6] [7] [12]

Peptide-specific notes for Indiana

Peptide-specific notes for Indiana
PeptideNote
SemaglutideAvailable branded by prescription, including by telehealth under Indiana Code 25-1-9.5. Compounded semaglutide is limited to documented patient-specific needs since the 503A grace period ended April 22, 2025, and Indiana compounders must now use FDA-registered bulk sources with a certificate of analysis. [2] [6] [11]
BPC-157Not FDA approved and not on the 503A bulks list; its nomination was withdrawn in April 2026. On October 28, 2026 HHS released a draft enforcement discretion policy covering single-ingredient BPC-157 compounded by a state-licensed pharmacy by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's tested substance, with serious adverse events reported to FDA. It is not an FDA approval, is not binding, and does not cover blends such as Wolverine. FDA's drug center recommended against listing; the advisory committee voted in favor (HHS policy, Appendix B). Indiana's 2026 law also requires the bulk substance to come from an FDA-registered establishment with a certificate of analysis. [6] [9] [10] [13] [14]

Frequently asked questions

Can I start GLP-1 treatment in Indiana through telehealth?

Yes. Indiana Code 25-1-9.5 lets an Indiana-licensed prescriber issue a prescription to a telehealth patient the prescriber has not examined in person, provided they verify who and where you are, keep a medical record, and meet the standard of care. The chapter does not settle whether a visit with no live contact is enough for a new patient. It counts store and forward technology as telehealth, but an Internet questionnaire with a new patient does not count as telehealth, and the practitioner must discuss the diagnosis with you. [2] [5]

What did Indiana's 2026 compounding law change?

Senate Enrolled Act 282, signed March 5, 2026, requires bulk drug substances used in compounding to come from FDA-registered manufacturers with a certificate of analysis, mostly effective July 1, 2026, and requires medical spas to register with the Medical Licensing Board beginning January 1, 2027. [6]

Do medical spas in Indiana need a license to give GLP-1 injections?

Starting January 1, 2027, medical spas must register with the Medical Licensing Board of Indiana, designate a responsible practitioner, and report serious adverse events under Senate Enrolled Act 282. The prescription and any compounded product must still meet federal and state pharmacy rules. [6]

What does an out-of-state pharmacy need to ship compounded peptides to Indiana?

An Indiana nonresident pharmacy license from the Indiana Board of Pharmacy under Indiana Code 25-26-17. Check the Professional Licensing Agency lookup before ordering. [1] [7]

Sources

Numbered citations above point to these primary sources: the state statute or rule, the pharmacy board, federal FDA guidance, and the FDA warning letters and studies behind what is offered.

  1. [1]Indiana Board of Pharmacy, Indiana Professional Licensing Agency
  2. [2]Indiana Code 25-1-9.5, Telehealth services and prescriptions (Indiana General Assembly, 2026 Indiana Code)
  3. [3]Senate Enrolled Act 282 (2026), enrolled text, Public Law 136, adding Indiana Code 16-42-22.5
  4. [4]856 Indiana Administrative Code Article 1, Pharmacies and Pharmacists (including Rule 30, sterile pharmaceuticals)
  5. [5]Indiana Professional Licensing Agency: telehealth
  6. [6]Indiana General Assembly, Senate Bill 282 (2026), Compounding drugs; registration of medical spas
  7. [7]Indiana Code Title 25, Article 26, Chapter 17, Nonresident pharmacies
  8. [8]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
  9. [9]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
  10. [10]FDA: Pharmacy Compounding Advisory CommitteeFDA

Cite this page

Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.

APA style
PeptideAgent. (2026, October 28). Are peptides legal in Indiana?. https://peptideagent.ai/legal/indiana
HTML link
<a href="https://peptideagent.ai/legal/indiana">Are peptides legal in Indiana?</a>, PeptideAgent, updated October 28, 2026.